Follicle-stimulating hormone receptor

Global Polycystic Ovary Syndrome (PCOS) Market Study, 2015-2026: Key Marketed & Pipeline Drugs, Clinical Trials, Patent Information, 10-Year Disease Incidence Forecast, Licensing & Acquisition Deals - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020
Health, Pharmaceutical, Branches of biology, Endocrine system, Hormones, RTT, G protein-coupled receptors, Human reproduction, Polycystic ovary syndrome, Signal transduction, Hormone receptor, Follicle-stimulating hormone receptor, Estrogen, Pavinetant

This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Points: 
  • This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
  • The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor.
  • Therapies in the pipeline for PCOS focus on targets such as AMP-activated protein kinase, neurokinin receptor, and gonadotropin-releasing hormone receptor.
  • Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.